Top

PharmacoEconomics

Published in:

01-01-2010 | Commentary

Adverse Drug Interactions

Moving from Perception to Action

Authors: Ryan Mayhew, June M. McKoy, Thanh Ha Luu, Isaac Lopez, Melissa Frick, Dr Charles L. Bennett

Published in: PharmacoEconomics | Issue 1/2010

Excerpt

The use of highly active antiretroviral therapy (HAART) has been exceptionally effective in improving the mortality and quality of life of patients with HIV/AIDS. Patients who are receiving HAART develop less resistance to individual drugs and typically experience less toxicity than those receiving single-agent therapy. Since HIV/AIDS was first discovered in 1981, 32 agents have been approved by the US FDA, including 26 individual agents and six combinations.[1] However, drug-drug interactions remain a significant concern as new therapeutic agents and classes emerge and fresh combinations of established regimens are explored. …

US FDA. Antiretroviral drugs used in the treatment of HIV infection [online]. Available from URL: http://www.fda.gov/ForConsumers/byAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm118915.htm [Accessed 2009 Aug 11]

Hellinger F, Encinosa W. The cost and incidence of prescribing errors among privately insured HIV patients. Pharmacoeconomics 2010; 28 (1): 35–46CrossRef

Important new pharmacokinetic data for reyataz (atazanavir sulfate) in combination with viread (tenofovir disoproxil fumarate): dear healthcare provider letter from Bristo-Myers Squibb Company. 2003 Aug 8 [online]. Available from URL: http://www.thebody.com/content/art13835.html?ts=pf [Accessed 2009 Jul 12]

Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2005 Apr 7 [online]. Available from URL: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL04072005001.pdf [Accessed 2009 Jul 12]

Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2004 Oct 29 [online]. Available from URL: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL10292004002.pdf [Accessed 2009 Jul 12]

Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48 (6): 2091–6CrossRef

Santoro MM, Bertoli A, Lorenzini P, et al. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study. AIDS Patient Care STDS 2008; 22 (1): 7–16CrossRef

Orrick JJ, Steinhart CR. Atazanavir. Ann Pharmacother 2004; 38 (10): 1664–74CrossRef

Johnson M, Grinsztein B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. Aids 2005; 19 (7): 685–94CrossRef

10.

Foley KA, Foster SA, Meadows ES, et al. Assessment of the clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure. Med Care 2007; 45 (9): 902–6CrossRef

11.

Logan JE, Riley AW, Barker LE. Parental mental and painrelated health and pediatric ambulatory care sensitive emergency department visits and hospitalizations. Health Serv Res 2008; 43 (2): 656–74CrossRef

12.

Nieves JW. Nutritional therapies (including fosteum). Curr Osteoporos Rep 2009; 7 (1): 5–11CrossRef

13.

Piedra PA, Schulman KL, Blumentals WA. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics 2009; 124 (1): 170–8CrossRef

14.

Taylor CA, Braza D, Rice JB, et al. The incidence of peripheral nerve injury in extremity trauma. Am J Phys Med Rehabil 2008; 87 (5): 381–5CrossRef

15.

Wynn ML, Chang S, Peipins LA. Temporal patterns of conditions and symptoms potentially associated with ovarian cancer. J Womens Health 2007; 16 (7): 971–86CrossRef

16.

Yacub JN, Rice JB, Dillingham TR. Nerve injury in patients after hip and knee arthroplasties and knee arthroscopy. Am J Phys Med Rehabil 2009; 88 (8): 635–41; quiz 642–4, 691CrossRef

17.

Schneider JE, Li P, Klepser DG, et al. The effect of physician and health plan market concentration on prices in commercial health insurance markets. Int J Health Care Finance Econ 2008; 8 (1): 13–26CrossRef

18.

Boulet SL, Grosse SD, Honein MA, et al. Children with orofacial clefts: health-care use and costs among a privately insured population. Public Health Rep 2009; 124 (3): 447–53CrossRef

19.

Mucha L, Masia NA, Axelsen KJ. Per-patient-per-month drug costs inMedicare Part D protected classes. Pharmacoeconomics 2006; 24: 79–84CrossRef

20.

Ye X, Gross CR, Schommer J, et al. Initiation of statins after hospitalization for coronary heart disease. J Manag Care Pharm 2007; 13 (5): 385–96PubMed

21.

Owusu-Edusei Jr K, Tejani MN, Gift TL, et al. Estimates of the direct cost per case and overall burden of trichomoniasis for the employer-sponsored privately insured women population in the United States, 2001 to 2005. Sex Transm Dis 2009; 36 (6): 395–9CrossRef

22.

Balkrishnan R, Pollack M, Joish VN, et al. An economic evaluation of therapeutic alteration in the management of insomnia. Curr Med Res Opinion 2009; 25 (3): 663–9CrossRef

23.

Mark TL, Axelsen KJ, Mucha L, et al. Racial differences in switching, augmentation, and titration of lipid-lowering agents by Medicare/Medicaid dual-eligible patients. Am J Manag Care 2007; 13 Suppl. 3: S72–9

24.

Zhou F, Shefer A, Weinbaum C, et al. Impact of hepatitis A vaccination on health care utilization in the United States, 1996–2004. Vaccine 2007; 25 (18): 3581–7CrossRef

25.

Hansen RA, Shaheen NJ, Schommer JC. Factors influencing the shift of patients from one proton pump inhibitor to another: the effect of direct-to-consumer advertising. Clin Ther 2005; 27 (9): 1478–87CrossRef

26.

Cortes JE, Curns AT, Tate JE, et al. Trends in healthcare utilization for diarrhea and rotavirus disease in privately insured US children <5 years of age, 2001–2006. Pediatr Infect Dis J. Epub 2009 Jul 9

27.

Hansen RA, Schommer JC, Cline RR, et al. The association of consumer cost-sharing and direct-to-consumer advertising with prescription drug use. Res Social Adm Pharm 2005; 1 (2): 139–57CrossRef

28.

Wish J, Schulman K, Law A, et al. Health care expenditure and resource utilization in patients with anaemia and chronic kidney disease: a retrospective claims database analysis. Kidney Blood Press Res 2009; 32 (2): 110–8CrossRef

29.

Nair KV, Tang B, Van Den Bos J, et al. Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populations. Curr Med Res Opin 2009; 25 (2): 303–14CrossRef

30.

Boulet SL, Molinar NA, Grosse SD, et al. Health care expenditures for infants and young children with Down Syndrome in a privately insured population. J Pediatrics 2008; 153 (2): 241–6CrossRef

31.

Zhao Y, Kuo TC, Weir S, et al. Healthcare costs and utilization for Medicare beneficiaries with Alzheimer’s. BMC Health Serv Res 2008; 8: 108CrossRef

32.

Zhou F, Kyaw MH, Shefer A, et al. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med 2007; 161 (12): 1162–8CrossRef

33.

Ohsfeldt RL, Lage MJ, Rajagopalan K. Medication use, service utilization, and medical costs associated with new episodes of bipolar disorder: evidence from a retrospective claims database. Prim Care Companion J Clin Psychiatry 2007; 9 (4): 280–6CrossRef

34.

Yoon EY, Dombkowski KJ, Rocchini A, et al. Off-label utilization of antihypertensive medications in children. Ambul Pediatr 2007; 7 (4): 299–303CrossRef

35.

Schulman KL, Kohles J. Economic burden of metastatic bone disease in the US. Cancer 2007; 109 (11): 2334–42CrossRef

36.

Mirkin D, Murphy-Barron C, Iwasaki K. Actuarial analysis of private payer administrative claims data for women with endometriosis. J Manag Care Pharm 2007; 13 (3): 262–72PubMed

37.

Prescott JD, Factor S, Pill M, et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007; 13 (1): 44–52PubMed

38.

Insinga RP, Itzler RF, Pellissier JM. Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group ofUS health plans. Pharmacoeconomics 2007; 25 (2): 155–69CrossRef

39.

Wechsler J. Medicare opens access to Part D data. 2008 July 1 [online]. Available from URL: http://managedhealthcareexecutive.modernmedicine.com/mhe/Newswire/Medicareopens-access-to-Part-D-data/ArticleStandard/Article/detail/528032 [Accessed 2009 Aug 1]

Title: Adverse Drug Interactions
Moving from Perception to Action
Authors: Ryan Mayhew
June M. McKoy
Thanh Ha Luu
Isaac Lopez
Melissa Frick
Dr Charles L. Bennett
Publication date: 01-01-2010
Publisher: Springer International Publishing
Published in: PharmacoEconomics / Issue 1/2010
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI: https://doi.org/10.2165/11530370-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Adverse Drug Interactions

Moving from Perception to Action

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2010

Should Financial Incentives be Used to Differentially Reward ‘Me-Too’ and Innovative Drugs?

A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing

Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma

Erlotinib

The Cost and Incidence of Prescribing Errors Among Privately Insured HIV Patients

Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure and Coronary Heart Disease in the US